Generic drugmaker Hetero has received the Drug Controller General of India (DCGI) approval to manufacture and sell its generic version of Gilead’s Remdesivir for the treatment of Covid-19 patients in the country. The generic version will be marketed under the brand name ‘Covifor’ in India, Hetero said about the product that is being manufactured at its facility in Hyderabad. Chairman of Hetero Group of Companies B. Partha Saradhi Reddy said the approval of Covifor (Remdesivir), amid the increasing COVID-19 cases in the country, can prove to be a game-changer given the positive clinical outcomes.
Generic drugmaker Hetero has received the Drug Controller General of India (DCGI) approval to manufacture and sell its generic version of Gilead’s Remdesivir for the treatment of Covid-19 patients in the country. The generic version will be marketed under the brand name ‘Covifor’ in India, Hetero said about the product that is being manufactured at its facility in Hyderabad. Chairman of Hetero Group of Companies B. Partha Saradhi Reddy said the approval of Covifor (Remdesivir), amid the increasing COVID-19 cases in the country, can prove to be a game-changer given the positive clinical outcomes.
11.jpeg)
30.jpeg)
39.jpeg)
101.jpeg)
417.jpeg)
10.jpeg)
40.jpeg)
100.jpeg)
416.jpeg)
